or Try an Advanced Search...

    Technical Analysis for AURA - Aura Biosciences, Inc.

    Grade Last Price % Change Price Change
    C 8.75 -1.91% -0.17
    AURA closed down 1.91 percent on Wednesday, November 20, 2024, on 1.26 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Up Down Down
    Historical AURA trend table...
    Date Alert Name Type % Chg
    Lower Bollinger Band Walk Weakness 0.00%
    Below Lower BB Weakness 0.00%
    Down 3 Days in a Row Weakness 0.00%
    Down 4 Days in a Row Weakness 0.00%
    Down 5 Days in a Row Weakness 0.00%
    Lower Bollinger Band Touch Weakness 0.00%
    Oversold Stochastic Weakness 0.00%
    NR7 Range Contraction -1.91%
    Lower Bollinger Band Walk Weakness -1.91%
    Below Lower BB Weakness -1.91%
    Older End-of-Day Signals for AURA ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Lower Bollinger Band about 21 hours ago
    Fell Below Previous Day's Low about 21 hours ago
    Down 1% about 21 hours ago
    Possible NR7 1 day ago
    Rose Above Lower Bollinger Band 2 days ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    AURA Chart by TradingView
    Basic chart:

    Profile

    Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer. The company develops virus-like drug conjugates (VDC) technology platform to treat tumors of high unmet need in ocular and urologic oncology. Its AU-011, a VDC candidate, is being developed for the first line treatment of primary choroidal melanoma, a rare disease with no drugs approved. The company also develops AU-011 in additional ocular oncology indications, including choroidal metastases. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Cancer Tumor Rare Diseases Melanoma Neoplasms Uveal Melanoma

    Is AURA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 12 Aura Biosciences Reports Third Quarter 2024 Financial Results and Business Highlights
    Oct 31 One Aura Biosciences Insider Raised Stake By 232% In Previous Year
    Oct 21 Aura Biosciences: 2 Positive Bel-Sar Data Releases Brings Shareholder Value
    Oct 18 Aura stock rallies 16% on positive bladder cancer data for bel-sar
    Oct 17 Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
    Oct 4 Aura Biosciences, Inc. (NASDAQ:AURA) is a favorite amongst institutional investors who own 58%
    Sep 17 Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company
    Sep 12 Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
    Sep 3 Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
    Aug 26 Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
    See more AURA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.3782
    52 Week Low 6.63
    Average Volume 201,011
    200-Day Moving Average 8.41
    50-Day Moving Average 9.84
    20-Day Moving Average 10.32
    10-Day Moving Average 10.02
    Average True Range 0.57
    RSI (14) 32.89
    ADX 24.17
    +DI 15.11
    -DI 30.24
    Chandelier Exit (Long, 3 ATRs) 10.00
    Chandelier Exit (Short, 3 ATRs) 10.46
    Upper Bollinger Bands 11.77
    Lower Bollinger Band 8.88
    Percent B (%b) -0.04
    BandWidth 28.06
    MACD Line -0.20
    MACD Signal Line 0.09
    MACD Histogram -0.285
    Fundamentals Value
    Market Cap 431.02 Million
    Num Shares 49.3 Million
    EPS -1.95
    Price-to-Earnings (P/E) Ratio -4.49
    Price-to-Sales 0.00
    Price-to-Book 2.66
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 9.25
    Resistance 3 (R3) 9.30 9.18 9.16
    Resistance 2 (R2) 9.18 9.06 9.16 9.13
    Resistance 1 (R1) 8.97 8.98 8.91 8.92 9.11
    Pivot Point 8.85 8.85 8.83 8.83 8.85
    Support 1 (S1) 8.64 8.73 8.58 8.59 8.39
    Support 2 (S2) 8.52 8.65 8.50 8.37
    Support 3 (S3) 8.31 8.52 8.34
    Support 4 (S4) 8.26